Summary
\nThis article explores the ANPD\u2019s 2025 Tech Radar on neurotechnologies and how it reshapes compliance risks for Brazilian healthtechs\u2014especially in M&A contexts involving GDPR exposure. It outlines key regulatory concerns, the GDPR\u2019s extraterritorial impact, major due-diligence red flags, and the essential deliverables investors should require.<\/p>\n
Brazil\u2019s latest ANPD Tech Radar brings neurotechnologies to the forefront of data-protection compliance, exposing significant risks for healthtech companies and investors. With GDPR\u2019s extraterritorial reach, sensitive data processing, opaque AI, and cross-border transfers, data governance has become a critical M&A due-diligence factor requiring structured reviews and robust contractual safeguards.<\/p>\n
Brazil\u2019s Data Protection Authority (ANPD) released its 4th Tech Radar in June 2025, focusing entirely on neurotechnologies\u2014marking the first time the regulator targeted this field so directly. The report explores brain-computer interfaces, advanced wearables, AI-driven cognitive therapies, and predictive diagnostics, highlighting risks far beyond traditional health data processing.<\/p>\n
For investors and lawyers working M&A deals in Brazil\u2019s healthtech sector, this Radar signals that data protection is no longer a secondary compliance issue\u2014it is now a major source of legal, reputational, and operational risk.<\/p>\n
Many Brazilian healthtechs handle personal data from foreign individuals, particularly Europeans\u2014through expats, medical tourists, cross-border clinical trials, or partnerships with EU-based vendors. When this occurs, GDPR Article 3(2) extends jurisdiction to the Brazilian company, even without any EU establishment.<\/p>\n
GDPR Article 22 prohibits automated decision-making with significant effects unless strict safeguards are implemented\u2014making this a critical risk during due diligence.<\/p>\n
LGPD Impact (Brazil):<\/strong>\u00a0Breach of LGPD Art. 11 LGPD Impact (Brazil):<\/strong>\u00a0Invalid consent (Art. 7 & 11) LGPD Impact (Brazil):<\/strong>\u00a0Breach of LGPD Art. 28 & 33 LGPD Impact (Brazil):<\/strong>\u00a0Serious regulatory violation LGPD Impact (Brazil):<\/strong>\u00a0Non-compliance with ANPD Resolution CD n\u00ba 2 LGPD Impact (Brazil):<\/strong>\u00a0Mandatory (ANPD Res. 15\/2023) LGPD Impact (Brazil):<\/strong>\u00a0Arts. 33\u201335 Until Brazil receives an EU adequacy decision, SCCs and BCRs remain mandatory for compliant transfers.<\/p>\n A robust data-protection review is now essential in healthtech M&A. Key deliverables include:<\/p>\n Data protection is no longer secondary in healthtech M&A\u2014especially when neurodata is involved. With ANPD scrutinizing neurotechnologies and GDPR obligations extending across borders, investors must prioritize structured due diligence and strong contractual safeguards.<\/p>\n Yes\u2014ANPD treats neurodata as highly sensitive because it reveals cognitive, emotional, and health patterns.<\/p>\n Yes, via Article 3(2), whenever EU data subjects\u2019 information is processed.<\/p>\n Yes, until Brazil receives an EU adequacy decision.<\/p>\n Missing DPIAs, unclear legal bases, opaque algorithms, and irregular transfers.<\/p>\n","protected":false},"excerpt":{"rendered":" Summary This article explores the ANPD\u2019s 2025 Tech Radar on neurotechnologies and how it reshapes compliance risks for Brazilian healthtechs\u2014especially in M&A contexts involving GDPR exposure. It outlines key regulatory concerns, the GDPR\u2019s extraterritorial impact, major due-diligence red flags, and the essential deliverables investors should require. Introduction Brazil\u2019s latest ANPD Tech Radar brings neurotechnologies to […]<\/p>\n","protected":false},"author":754,"featured_media":33405,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12481,484,1379],"tags":[1712],"class_list":["post-33404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare","category-ma","category-privacy-data-protection","tag-brazil"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/posts\/33404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/users\/754"}],"replies":[{"embeddable":true,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=33404"}],"version-history":[{"count":1,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/posts\/33404\/revisions"}],"predecessor-version":[{"id":33413,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/posts\/33404\/revisions\/33413"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/media\/33405"}],"wp:attachment":[{"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=33404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/categories?post=33404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.legalmondo.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=33404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nGDPR Parallel (Europe):<\/strong>\u00a0Art. 9 (special categories)
\nPractical Recommendation:<\/strong>\u00a0Require full data-mapping and warranties<\/p>\nGeneric or \u201cclick-to-accept\u201d consents<\/h3>\n
\nGDPR Parallel (Europe):<\/strong>\u00a0Art. 6 + 7
\nPractical Recommendation:<\/strong>\u00a0Ensure all consents are granular, specific, and revocable<\/p>\nThird-party sharing without processor agreements<\/h3>\n
\nGDPR Parallel (Europe):<\/strong>\u00a0Art. 28
\nPractical Recommendation:<\/strong>\u00a0Verify existence and adequacy of all DPAs<\/p>\nMissing or incomplete ROPA<\/h3>\n
\nGDPR Parallel (Europe):<\/strong>\u00a0Art. 30
\nPractical Recommendation:<\/strong>\u00a0Make ROPA delivery a closing condition<\/p>\nNon-existent or conflicted DPO<\/h3>\n
\nGDPR Parallel (Europe):<\/strong>\u00a0Art. 37\u201339
\nPractical Recommendation:<\/strong>\u00a0Require interview + independence confirmation<\/p>\nNo DPIA for high-risk products<\/h3>\n
\nGDPR Parallel (Europe):<\/strong>\u00a0Art. 35
\nPractical Recommendation:<\/strong>\u00a0Include pre-closing DPIA audit clause<\/p>\nInternational transfers without safeguards<\/h3>\n
\nGDPR Parallel (Europe):<\/strong>\u00a0Arts. 44\u201350
\nPractical Recommendation:<\/strong>\u00a0Verify SCCs (2021\/2023) or adequacy status<\/p>\nReal Cases Illustrating the Scale of Risk<\/h3>\n
\n
Essential Due Diligence Deliverables<\/h2>\n
\n
Conclusion<\/h3>\n
FAQ<\/h3>\n
Is neurodata considered sensitive personal data under the LGPD?<\/h3>\n
Does GDPR apply to Brazilian companies with no EU presence?<\/h3>\n
Are SCCs still required for Brazil\u2013EU transfers?<\/h3>\n
What are the top investor red flags?<\/h3>\n